항암치료의원칙 순천향대학교병원 종양혈액내과박희숙
|
|
- Irma Fleming
- 5 years ago
- Views:
Transcription
1 항암치료의원칙 순천향대학교병원 종양혈액내과박희숙
2 Introduction 한국인에서암은지난 10 년간사망원인 1 위였으며, 암발생은지속적으로증가추세에있다. 최근암조기발견과암치료의발전으로암생존율이향상됨에따라생존기간뿐아니라암치료에의한장기적영향과생존자의삶의질에대한관심이높아지고있다. 한국인의주요암의 5 년상대생존율 : 46.3% (2002 년 ) 2
3 평균수명까지생존시암발생확률, 2003~2005 전체 남자 여자 평균수명 * (2005년) * 자료원 : 통계청 79 세 75 세 82 세 평균수명까지생존시암발생확률 29.6% (10 명중 3 명 ) 31.9% (3 명중 1 명 ) 25.5 % (4 명중 1 명 ) 1999~2002 년기준암발생확률전체 : 25.6% ( 기대여명 : 77 세 ) 남자 : 27.7% ( 기대여명 : 73 세 )/ 여자 : 22.2% ( 기대여명 : 81 세 ) 3
4 주요암종발생분율, 2003~2005 ( 단위 : %) 4
5 성별주요암종발생분율, 2003~2005 ( 단위 : %) 남자 여자 5
6 성별 5 년생존율추이 : 모든암 '93-'95 '96-'00 '01-' 전체남자여자 6
7 주요암의 5 년생존율국제비교 단위 : % 1) Ries LAG, et al (eds). SEER Cancer Statistics Review, , National Cancer Institute, ) National Cancer Center in Japan. Cancer Statistics in Japan,
8 암치료의목표 일차목표 : to eradicate the cancer( 암제거 ) 일차목표가불가능한경우 (Palliation, 완화요법 ) 증상의완화 생명연장 삶의질개선 ( 통증완화등 ) 8
9 수술 방사선치료 항암치료 항암화학요법 세포독성치료 면역요법 생물학적치료 유전자요법 대체요법 맞춤치료 (Tailored Therapy)( 표적치료 ) 9
10 용어정리 Neoadjuvant chemotherapy : 선행 ( 보조 ) 항암화학요법 Organ preservation : H & N cancer, Rectal cancer breast cancer (non-metastatic), Osteosarcoma Adjuvant chemotherapy: 보조항암화학요법 Colorectal, Breast, NSCLC, Osteosarcoma, Definitive CCRT : Inoperable NSCLC(non-metastatic), Esophageal cancer Palliative chemotherapy : 완치가불가한경우 Induction chemotherapy : 유도항암화학요법 Hematologic malignancy 완전관해를목적으로하는 CTx Salvage : 1 st line chemotherapy 실패한경우 10
11 항암화학요법 11
12 (Mitosis) CELL DIVISION CELL DIFFERENTIATION G 1 PERIOD G 2 PERIOD (Cell prepare to divide) CELL LIFE CYCLE TIME (CHROMOSOME REPLICATION) S-PHASE 12
13 항암제란??? 세포내의 DNA 에직접결합작용하여 DNA 의 replication, transcription, translation 을차단 핵산합성의대사경로에개입하여핵산합성을방해 세포분열을저해 암세포에대한세포독성을나타내는약제 13
14 Tumor cell Kinetics L1210 murine leukemia system 14
15 Dose / Therapeutic Index The degree of separation between toxic and therapeutic doses Anti-cancer drugs: narrow TI Dose-limiting toxicity (DLT) Maximum tolerated dose (MTD) 15
16 Chemotherapeutic agents 16
17 Alkylating agents Cyclophosphamide Ifosfamide most frequently used alkylating 폐암, 고환암, 육종, 악성임파종 agent Mesna protection for 유방암, 폐암, 난소암, 방광암, 악성 hemorragic cystitis 임파종, 호지킨씨병등 Parent form: no direct cytotoxic Vigorous hydration and frequent effects bladder empty must be activated to cytotoxic CNS effects forms by microsomal enzymes Maintain fluids intake and frequent bladder empty Hemorrhagic cystitis 17
18 Platinums Cisplatin 고환암, 폐암, 난소암, 자궁암, 방광암, 두경부암, 각종소화기암, 연부조직육종, 악성임파종 Vigorous hydration with diuresis to prevent renal toxicity Neurotoxicity Carboplatin Equivalent efficacy Less nephro-, oto- and neurotoxicity than DDP More frequent myelosuppression Exclusive renal excretion Hypomagnesemia and hypokalemia Highly emetogenic agent 18
19 Etoposide (VP-16) Plant product podophylotoxin Binds directly to topoisomerase II and DNA in a reversible ternary complex stabilized enzyme-dna complex Epipodophyllotoxins Topoisomerase II 폐암, 위암, 고환암, 악성림파종 Melosuppression, hypersensitivity reaction 19
20 Taxanes Paclitaxel 유방암, 난소암, 폐암, 두경부암, 위암, 방광암, 자궁암, 악성흑색종, 카포씨육종 Anaphylaxis: premedication!! Myalgia, arthralgia and peripheral neuropathy Docetaxel 유방암, 폐암, 두경부암, 난소암, 전립선암 Hypresensitivity reaction Capillary leak syndrome: pre- & post medication myalgia, general weakness Pacific yew tree European yew tree 20
21 What Are the Goals of Chemotherapy? 항암효과증대 : 적절한용량 (dose) 적절한스케쥴 (Schedule) 적절한투여방법 (Route) Efficacy Toxicity Cure, Control, Palliation 21
22 Toxicity Overview 세포독성항암제는정상세포와암세포를구별하지못한다 No magic bullet(?)( 마법의탄환이되지못함 ) 안정영역이좁다 (MTD, DLT) 세포분열이활발한정상조직즉골수세포, 소화기관모발세포등에급성독성이강하게나타남 특별한장기에발생하는독성 ( 심장, 신장폐등 ) 항암제에의한장기적합병증 22
23 Classification of chemotherapeutic toxicity onset Immediate hours to days Early days to weeks Delayed weeks to months Late months to years 23
24 Immediate Toxicity (Hours to Days) Common to many agents Predominantly seen with one or two agents Nausea/vomiting Local tissue necrosis Phlebitis Hyperuricemia Renal failure Anaphylaxis Skin rash Hemorrhagic cystitis(ctx) Hypocalcemia(Mithramycin) Facial flushing(mithramycin) Radiation recall(actinomycin-d) Fever/chills(Bleomycin) Hypertension(Procarbazine) Hypotension(Etoposide) 24
25 Side Effects of Chemotherapy Mucositis Alopecia Pulmonary fibrosis Nausea/vomiting Diarrhea Cystitis Sterility Myalgia Neuropathy Cardiotoxicity Local reaction Renal failure Myelosuppression Phlebitis 25
26 Specific Organ Toxicity (1) 신장 : cisplatin, methotrexate 소화기 ( 구내염, 설사 ): 5-fluorouracil, anthracyclines, methotrexate 간 : L-asparaginase, methotrexate, 6-mercaptopurine 심장 : anthracycline, cyclophosphamide 폐 : bleomycin, busulfan, BCNU 신경계 : 말초신경계 - vincristine, platinum compounds 중추신경계 - procarbazine, L-asparaginase 26
27 Specific Organ Toxicity (2) 생식기 : alkylating agents, vinblastine, procarbazine 색소침착 : 5-fluorouracil, bleomycin 수족증후군 (hand-foot syndrome): 5-FU(infusion), oral fluoropyrimidine, Sunitinib, Sorafenib, TSU-68. 출혈성방광염 : cyclophosphamide, ifosfamide 피부괴사 (vesicants): anthracyclines, vinca alkaloids, mitomycin C 이차암 : alkylating agents, epipodophylotoxin, nitrosourea, procarbazine 27
28 Doxorubicin 유방암, 악성림파종, 연부조직육종, 폐암, 위암, 간암, 백혈병 Intercalating into DNA, thereby altering DNA structure, replication and topoisomearse II function Toxicity Myelosuppression, alopecia, emesis and mucositis Cardiac toxicity Vesicant Skin necrosis caused by extravasation of ADR 28
29 Hand-Foot Syndrome caused by capecitabine 29
30 Irritant Drugs Pain at the injection site or along the vein, with or without an inflammatory reaction Camustine CDDP DTIC (dacabazine) 5-FU Bleomycin Paclitaxel Vinorelbine Phlebitis caused by vinorelbine (Navelbine) 30
31 Vesicant Drugs Anti-cancer chemotherapeutic agent capable of forming a blister and/or causing tissue destruction. Actinomycin Daunorubicin Doxorubicin Epirubicin Idarubicin Mitomycin Vinblastine Vincristine Extravasation caused by doxorubicin 31
32 Chemoport 32
33 Early Toxicity (days to weeks) Comm Predominantly seen on Leukopenia Thrombocytopenia Alopecia Stomatitis Diarrhea Megaloblastosis Paralytic ileus(vcr) Hypercalcemia(Estrogen, Antiestrogen) Hypomagnesemia(cisplatin) Psychosis(Corticosteroids) DIC(L-asparaginase) Pancreatitis(L-asparaginase) Fluid retension(estrogen, corticosteroids, taxanes) Pul. infiltrates(mtx, Bleomycin) Hyperglycemia(corticosteroids) Cerebral ataxia(5-fu) Ototoxicity(cisplatin) 33
34 Nausea and Vomiting Highly emetogenic drugs (level 5) Cisplatin ( >50 mg/m) Nitrosourea Cyclophosphamide ( > 1500 mg/m) DTIC Streptozotocin Mechlorethamine 34
35 Bone Marrow Suppression(1) Most common dose-limiting toxicity - Neutropenia Nadir: 1-2 weeks Recovery within 3-4 weeks - Thrombocytopenia - Anemia 35
36 Oral Mucositis Incidence Standard chemotx: 35-40% BMT or PBSCT : 75% Radiotherapy in head and neck cancer : >90% Clinical outcome Significant pain Quality of life Nutritional compromise Portals of entry of microorganism sepsis Suboptimal tumor response direct impact on survival 36
37 Specific Organ Toxicity (1) 신장 : cisplatin, methotrexate 소화기 ( 구내염, 설사 ): 5-fluorouracil, anthracyclines, methotrexate 간 : L-asparaginase, methotrexate, 6-mercaptopurine 심장 : anthracycline, cyclophosphamide 폐 : bleomycin, busulfan, BCNU 신경계 : 말초신경계 - vincristine, platinum compounds 중추신경계 - procarbazine, L-asparaginase 37
38 Specific Organ Toxicity (2) 생식기 : alkylating agents, vinblastine, procarbazine 색소침착 : 5-fluorouracil, bleomycin 수족증후군 (hand-foot syndrome): 5-FU(infusion), oral fluoropyrimidine 출혈성방광염 : cyclophosphamide, ifosfamide 피부괴사 (vesicants): anthracyclines, vinca alkaloids, mitomycin C 이차암 : alkylating agents, epipodophylotoxin, nitrosourea, procarbazine 38
39 Delayed Toxicity (weeks to months) Common to many agents Anemia Aspermia Hepatocellular damage Hyperpigmentation Pulmonary fibrosis Predominantly seen with one or two agents Peripheral neuropathy(vcr) Cardiac neurosis(adr, CTX) Cushing s syndrome(corticosteroids) SIADH(CTX, VCR) Musculinization(Androgen) Raynaud s phenomenon(bleomycin) Feminization(Estrogen) Cholestatic jaundice(6-mp) Addison-like syndrome(busulfan) Lacrimal duct fibrosis(5-fu) Hemolytic uremic syndrome(mmc) 39
40 Late Toxicity (months to years) Common to many agents Sterility Hypogonadism Premature menopause Acute leukemia, MDS Lymphoma Solids tumors Predominantly seen with one or two agents Hepatic fibrosis/cirrhosis(mtx) Encephalopathy(MTX, CNS RT) Carcinoma of the bladder(ctx) Osteoporosis(Corticosteroids) Cataracts(Busulfan) 40
41 부작용을예방또는최소화하는방법 전처치약제 진토제 Hydration, 수액요법 부작용예방약 휴식혹은용량감소 중심정맥관삽입 정기적인검사 + 초기에치료, 조혈촉진인자 나자신도믿지말라. 가장중요한것은? 환자를돌보는사람의마음가짐,! 41
42 세포독성항암제의문제점 선택성결여 (Low therapeutic index) 약제저항 (Drug resistance) 독성 ( 정상세포손상 ) 42
43 Paradigm shift : Cytotoxic agents : Combination : Targeted agents 43
44 Targeted Drug 표적치료 (Targeted Therapy) Personalized Therapy Indivisualied Therapy 맞춤치료 (Tailored Therapy) 44
45 표적치료제 (Molecular target) 암세포와정상세포를선택적으로구분할수있는 "molecular target" 을대상으로소위 small molecule 에대한연구가진행되고있다. small molecule 이란약 500 kd 이하의질량을갖는작은제재로암조직으로의약제투여가용이하고, 약제내성과도관련되지않는장점을갖고있다. 1. Growth factor and Growth factor receptor : monoclonal antibody, tyrosine kinase inhibitor 2. Angiogenesis inhibitor 3. Signal inhibitors 4. Vaccines 5. Gene and antisense therapy 45
46 Targets 46
47 Target: Ligand, Receptor, TK 47
48 Imatinib (Gleevec) 48
49 49
50 Nomenclature of Mab -omab -ximab -zumab -umab Rituximab Cetuximab Bevacizumab Trastzuzumab Panitumumab 50
51 Targeted Agents Small Molecule (-nib) Imatinib (Glivec R ) BCR/ABL, c-kit TK CML, GIST Gefitinib (Iressa R ) EGFR TK NSCLC Erlotinib (Tarceva R ) EGFR TK NSCLC, Pancreatic C Sorafenib (Nexavar R ) Raf, VEGFR, PDGFR TK Clear cell RCC Hepatoma Sunitinib (Sutene R ) VEGFR, PDGFR TK RCC, GIST 51
52 Targeted agent Y Monoclonal Antibody (-mab) Bevacizumab (Avastin R ) VGEF mcrc, NSCLC, MBC Rituximab (Mabthera R ) CD20 NHL Trastuzumab (Herceptin R ) Her2/neu EBC, MBC Cetuximab (Erbitux R ) EGFR mcrc, HNC Panitumumab EGFR mcrc Bortezomib (Velcade R ) Proteasome MM 52
53 Summary Compounds Main Antiangiogenic Targets Main Antiproligerative Targets VEGF VEGFR PDGFR EGFR Raf c-kit BCR-ABL Imatinib O O Sorafenib O O O Sunitinib O O O Gefitinib Erlotinib O O Bevacizumab O Cetuximab O 53
54 R. Herbst,
55 감사합니다 박희숙 55
Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationTargeted Therapy Vijay Narang
25 Volume 1, Issue 1, January 2013, Online: Targeted Therapy Vijay Narang ABSTRACT This is a review on targeted therapy that blocks the growth and spread of cancer by interfering with specific molecules
More informationDrug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University
More informationChemotherapy and the development of novel therapeutics
SCPA607-Pathobiology and mechanisms of cancer Chemotherapy and the development of novel therapeutics Somphong Narkpinit, M.D. Department of Pathobiology Faculty of Science Mahidol University E-mail : somphong.nar@mahidol.ac.th
More informationthrough the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.
Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this
More informationYear III Pharm D. Dr. V. Chitra
Year III Pharm D. Dr. V. Chitra 50.2 Rang Etiolopathology Cell Cycle = Growth, Division 18_01_cell_cycle.jpg Characteristics of Cancer Cells The problem: Cancer cells divide rapidly (cell cycle is accelerated)
More informationIntroduction to Antineoplastic Prescribing
Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationAntineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea
Antineoplastic Drugs Pharmacology Chapter 51 Carolyn Wright, RN, BSN Ford, S. & Roach, S. (2010). Roach's introductory clinical pharmacology (9 th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationCancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018
Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Modalities of Cancer Chemotherapy Curative: Only in 10-15% of cases. In certain disseminated
More informationPrinciples of Cancer Treatment. Objectives 8/29/2014 SURGERY. Megan Kilpatrick, RN OCN, CHPN MultiCare Health System
Principles of Cancer Treatment Megan Kilpatrick, RN OCN, CHPN MultiCare Health System Objectives Describe the principles of cancer treatment Surgery Chemotherapy Biotherapy and Targeted Therapy Complementary
More information*Combination therapy: *Cancer drugs are divided into groups: I) DNA binding agents (Intercalating and Alkylating agents) 2 types: Doxorubicin
*Combination therapy: - Cancer is heterogeneous, and resistant anticancer drugs are common, so combination of drugs together is needed in order to attack cancer. *Cancer drugs are divided into groups:
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationPart III: Anticancer Agents Antibiotics
Part III: Anticancer Agents Antibiotics Classification of Antibiotics: Anthracycline Mitomycin C Bleomycin Actinomycin D Antibiotics Anthracyclines Anthracycline antibiotics are characterized by a planner
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationCANCER CHEMOTHERAPY Michael Lea
CANCER CHEMOTHERAPY 2010 Michael Lea Cancer Chemotherapy - Lecture Outline 1. Targets for cancer chemotherapy 2. Classification of anticancer drugs 3. Cell cycle specificity 4. Drug resistance 5. New approaches
More informationDRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
More informationObjectives. Principles of Cancer Treatment SURGERY 2/9/2015. Describe modalities and mechanism of action for the following cancer treatments
Objectives Principles of Cancer Treatment Kelly B. Weaver, RN, MSN, OCN, ACNS-BC MultiCare Health System Describe modalities and mechanism of action for the following cancer treatments Chemotherapy Biotherapy
More information2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues)
CANCER DRUG CLASSES The classes of drugs currently used in the cancer clinic are 1. DNA Binding Agents (intercalating and alkylating agents) 2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation)
More informationMedication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationChemotherapy Teaching Points
Chemotherapy Teaching Points 1. Antimetabolites - These drugs are analogs of vital co-factors in DNA or RNA synthesis. They competitively inhibit DNA or RNA production, or are directly incorporated into
More informationPrinciples of chemotherapy. Ann De Becker Klinische Hematologie UZ Brussel
Principles of chemotherapy Ann De Becker Klinische Hematologie UZ Brussel History Paul Ehrlich (1854-1915) 1909 Arsphenamine for syphilis treatment Definition: Use of any drug to cure any disease Antineoplastic/cytotoxic
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationEssentials. Oncology Practise Essentials. Oncology Basics. Tutorial 2. Cancer Chemotherapy
Practise Practise This tutorial introduces you to the history, goals of therapy, classification, and clinical uses of chemotherapy. It also reviews some of the barriers to successful therapy. Goals and
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationCell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger
Cell, Volume 141 Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Figure S1. RTK Mutations in Diseases Locations of gain-of-function (green arrows)
More informationCancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018
Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 االدوية Polyfunctional Alkylating Agents االستخالبية متعددة الوظائف Not cell cycle-specific.
More informationWhy do patients take herbs and nutritional supplements?
Why do patients take herbs and nutritional supplements? Dissatisfaction with conventional medicine > Relieve cancer-related symptoms > Treat adverse effects of anticancer drugs > Treat cancer > Promote
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationHospice Skills Checklist
_ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationManagement of Toxicities of the New Oncologic Agents
Management of Toxicities of the New Oncologic Agents Kevin P. Hubbard, DO, HMDC, MACOI Professor and Chair - Department of Specialty Medicine Kansas City University - College of Osteopathic Medicine Financial
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationTherapy Side Effects
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Therapy Side Effects Therapy Side Effects Versions 2004 2011: Albert / Bischoff / Costa / Friedrichs / Göhring / Jackisch/
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More informationEssentials. Oncology Practise Essentials. Oncology Basics. Tutorial 5. Toxicity of Chemotherapy Agents
Toxicity of This tutorial reviews the common clinical toxicities of chemotherapy gastrointestinal, dermatological, secondary malignancies, and infertility and their treatment and management. Goals and
More informationPrinciples of chemotherapy
Principles of chemotherapy Chemotherapy first coined by Paul Ehrlich Aim to selectively destroy cancer cells whilst relatively sparing tumours cells Growth characteristics of cancer cells allows for selective
More informationAnswer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.
UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 CLINICAL THERAPEUTICS 8: ONCOLOGY PHA-MHCY Time allowed: 2 hours Part ONE Answer ALL questions. For each question, there
More informationPRODUCT MONOGRAPH GEMCITABINE INJECTION
PRODUCT MONOGRAPH Pr GEMCITABINE INJECTION Concentrate Sterile Solution for Injection Gemcitabine (as Gemcitabine Hydrochloride) 40 mg gemcitabine per ml 200 mg/5 ml, 1 g/25 ml, 2 g/50 ml Antineoplastic
More informationOncology Skills Checklist
_ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationLecture 10: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids. Vincristine (Oncovin):
Lecture 10: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids Vincristine (Oncovin): Uses: Acute leukemia, Hodgkin s lymphoma (part of the MOPP, COPP, BEACOPP regimens); non- Hodgkin
More informationEC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen
y Systemic Anti Cancer Treatment Protocol EC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen PROTOCOL REF: MPHAECANBR (Version No: 1.0) Approved for use in: ER positive, HER2 negative ( Luminal
More information4. Shown below is the structure of doxorubicin (Adriamycin). What is true about this agent?
Midterm 2: 3 points each (except final question worth 1 point 1. A useful regimen for treating colorectal cancer is FOLFIRI. What is true about this regimen? A. The regimen includes folinic acid, 5-fluorouracil
More informationPRODUCT MONOGRAPH. Ready-to use solution. 38 mg/ml gemcitabine (as gemcitabine hydrochloride) 200 mg / 5.3 ml, 1 g / 26.3 ml, and 2 g / 52.
PRODUCT MONOGRAPH Pr GEMCITABINE INJECTION Ready-to use solution 38 mg/ml gemcitabine (as gemcitabine hydrochloride) 200 mg / 5.3 ml, 1 g / 26.3 ml, and 2 g / 52.6 ml Sterile THERAPEUTIC CLASSIFICATION
More informationBreast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer
Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationLecture 11: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids (we will discuss 3) Vincristine (Oncovin):
Lecture 11: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids (we will discuss 3) Vincristine (Oncovin): Uses: Acute leukemia, Hodgkin s lymphoma (part of the MOPP, COPP, BEACOPP
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationPRODUCT MONOGRAPH. Gemcitabine for Injection. 200 mg, 1 g and 2 g gemcitabine (as gemcitabine hydrochloride) per vial House Std. Antineoplastic Agent
PRODUCT MONOGRAPH Pr Gemcitabine for Injection 200 mg, 1 g and 2 g gemcitabine (as gemcitabine hydrochloride) per vial House Std. Antineoplastic Agent Accord Healthcare Inc. 3100, Steels Avenue East, Markham,
More informationIntroduction to Targeted Therapy
Introduction to Targeted Therapy Cancer remains the second leading cause of death in the United States, despite the significant advances in cancer therapy made over the past several decades. Many factors
More informationNew Zealand Datasheet
Name of Medicine NAVELBINE Vinorelbine 10mg/mL Injection New Zealand Datasheet Presentation NAVELBINE Injection is a clear colourless to pale yellow solution in water for injections containing 10 mg vinorelbine
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationCancer Incidence and Mortality
Cancer Incidence and Mortality Cancer is a common disease. One in three people in the Western World contract cancer and one in four die from it. The cure rate is 50% Cancer is strongly age-related, the
More informationPharmacology. Cell cycle
Objectives: To define chemotherapy To define the common classes of drugs used and mechanism of action To identify dermatologic side effects of chemotherapeutic drugs Chemotherapy Definition: the treatment
More informationProduct Visual Guide
Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.
More informationChemotherapy and its side effects.
Chemotherapy and its side effects. Maria Ronson Lead Chemotherapy Nurse Learning outcomes How it works on cells terminology. Understand and learn about side effects of chemotherapy. Management of side
More informationFEC-D with HP Fluorouracil, Epirubicin, Cyclophosphamide, Followed by Docetaxel, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Approved for use in: Neoadjuvant breast cancer: The neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early breast cancer at high risk of recurrence Interim CDF funding from November
More informationREVIEW OF CHEMOTHERAPY PHARMACOLOGY. Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand
REVIEW OF CHEMOTHERAPY PHARMACOLOGY Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives 1. Identify the mechanism of action of the major classes
More informationREVIEW OF CHEMOTHERAPY PHARMACOLOGY. Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand
REVIEW OF CHEMOTHERAPY PHARMACOLOGY Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives 1. Identify the mechanism of action of the major classes
More informationAnti-cancer drugs. Introduction : Body : 1) Alkylating Agents
Anti-cancer drugs Introduction : In this journal I will try to explain what is anti-cancer agents, how they work, how can they inhibit the growth of tumor and what is the advantages and disadvantages of
More informationTargeted therapy in Cancer
Targeted therapy in Cancer Dr TRI WIDYAWATI M.Si Dr. DATTEN BANGUN MSc,SpFK Bagian Farmakologi dan Terapeutik, Fakultas Kedokteran Universitas Sumatera Utara Introduction Surgery, radiation and chemotherapy
More informationPRINCIPLES OF ONCOLOGICAL TREATMENT: CHEMO-, ENDOCRIN AND TARGETED THERAPIES. Magdolna Dank
PRINCIPLES OF ONCOLOGICAL TREATMENT: CHEMO-, ENDOCRIN AND TARGETED THERAPIES Magdolna Dank Modalities of treatment in cancer Surgery Radiotherapy 1/3 of patients can be cured, effective when tumor has
More informationChapter 37. Media Directory. Tumor (neoplasm) Cancer (carcinoma) Causes of Cancer. Drugs for Neoplasia
Chapter 37 Media Directory Drugs for Neoplasia Slide 39 Slide 41 Cyclophosphamide Animation Methotrexate Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cancer (carcinoma) Tumor (neoplasm)
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationCancer Incidence and Mortality
Cancer Incidence and Mortality Cancer is a common disease. One in three people in the Western World contract cancer and one in four die from it. The cure rate is 50% Cancer is strongly age-related, the
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationDRUGS YOU NEED TO KNOW
jfitzake@d.umn.edu Page 1 of 7 DRUGS YOU NEED TO KNOW ALKYLATING AGENTS (blue cards) BUSULFAN CARMUSTINE (BCNU) CYCLOPHOSPHAMIDE DACARBAZINE LOMUSTINE (CCNU) MECHLORETHAMINE MELPHALAN THIOTEPA NATURAL
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More information"Pharmacology. Anticancer Drugs
I "Pharmacology Anticancer Drugs Include: 1) Cytotoxic drugs. 2) Isotopes: which emit β-irradiation that destroy cancer cells, e.g. I 131, P 32, Au 193 3) Hormones: A- Steroids: prednisolone used in leukemia
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationLecture 8: Antibodies & Antibody Conjugates - targeted cell killing agents
Lecture 8: Antibodies & Antibody Conjugates - targeted cell killing agents Monoclonal antibodies can be identified quickly by the mab at the end of their name. They are can be naked or conjugated depending
More informationGuidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationPulmonary Complications of Cancer Treatment
Pulmonary Complications of Cancer Beth Zigmund, MD Objectives (Preliminary Version) Beth Zigmund, MD Develop awareness of the myriad pulmonary complications of cancer treatment and of challenge in making
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationColorectal Cancer Therapy and Associated Toxicity
Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated
More informationOncology Basics. Essentials. Hormonal/Endocrine Therapy, Immunotherapy and Targeted Therapy. Tutorial 4. Oncology Practise Essentials
Part 2: Pharmacology of Cancer Chemotherapy Immunotherapy and Targeted Therapy The pharmacology of the large family of anticancer drugs is the subject of this tutorial. It will give you the background
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationPHARMACOLOGIC THERAPY OF CANCER. Marshall A Levine, MD Cancer Center at GBMC
PHARMACOLOGIC THERAPY OF CANCER Marshall A Levine, MD Cancer Center at GBMC Disclosures Stock holdings in Genentech, Amgen Will discuss some non-fda approved uses of cetuximab, panitumumab, erlotinib,
More informationCONTRAINDICATIONS Patients with a known hypersensitivity to gemcitabine (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GEMCITABINE injection safely and effectively. See full prescribing information for GEMCITABINE injection.
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More information